Author

R. Bhayadia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1

Frequent Co-Authors

D. Heckl· 3 shared J.-H. Klusmann· 3 shared A. Sinz· 2 shared C. Beyer· 2 shared C. Ihling· 2 shared D. Reinhardt· 2 shared E. Regenyi· 2 shared H. Issa· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Heckl

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RUNX1 isoform disequilibrium in the development of trisomy 21 associated myeloid leukemia

S. Gialesaki, D. Brauer-Hartmann, R. Bhayadia, O. Alejo-Valle, H. Issa, E. Regenyi, C. Beyer, M. Labuhn, C. Ihling, A. Sinz, M. Glass, S. Huttelmaier, S. Matzk, L. Schmid, F. J. Struwe, , J.-H. Klusmann

This study identifies RUNX1 isoform imbalance as a key driver of trisomy 21-associated myeloid leukemia and shows that restoring this balance can reverse leukemogenesis.

bioRxiv · Mar 7, 2022 · PreprintCancer Biology

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core

J. Grimm, R. Bhayadia, L. Gack, D. Heckl, J.-H. Klusmann

This study shows that combining LSD1 and JAK-STAT inhibition effectively targets Down syndrome-associated myeloid leukemia by synergistically repressing cell division and enhancing immunogenicity.

bioRxiv · Jan 14, 2022Cancer Biology

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

O. Alejo-Valle, K. Weigert, R. Bhayadia, M. Ng, S. Emmrich, C. Beyer, K. Schuschel, C. Ihling, A. Sinz, M. Flasinski, H. Issa, E. Regenyi, M. Labuhn, D. Reinhardt, M.-L. Yaspo, , J.-H. Klusmann

This paper identifies ARID3A repression by miR-125b as a key driver of megakaryoblastic leukemia, showing that restoring ARID3A expression can reverse differentiation arrest in AMKL.

bioRxiv · Apr 26, 2021Cancer Biology